Drug Pipeline

 

Agastiya Biotech’s portfolio of novel drug candidates are designed
to combat disease at the stem cell and genetic mutation source.

 

Drugs Designed to Eradicate Cancer at Source

In 2018, Agastiya Biotech took a topical botanical treatment for psroriasis through clinicial trials in India resulting in a first of its kind licensing agreeement with Lupin Pharmaceuticals.  Since that time Agastiya Biotech has made rapid breakthroughs in small molecule design and engineering with a focus on cancer therapeutics.  Our pipeline is focused on areas for which the unmet medical need is greatest and for which there are few effective therapies.  Our product candidates are at the leading edge of genetic therapies in the industry today.

The following table illustrates our product candidates and their status in ongoing development:

Product Candidate Pipeline